Skip to content

Effects of transcranial direct current stimulation (tDCS) on motor and cognitive function in patients with Parkinson's disease

Effects of transcranial direct current stimulation (tDCS) on motor and cognitive function in patients with Parkinson's disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037213
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-08-30
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Control group:regular treatment

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as idiopathic Parkinson's disease according to Diagnostic criteria of Parkinson's disease; (2) Age between 50-70 years; (3) Hoen and Yahr 1-3; (4) The drug dose was stable 2 months before participating in the trial; (5) Can walk for 6 minutes without support and crutches and able to stand and sit; (6) MMSE>24, can understand and coordinate the treatment; (7) Able to read and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Combined with other mental diseases; (2) Patients with epilepsy and those taking drugs that can cause epilepsy; (3) Combined with other organic intracranial diseases, such as Alzheimer's disease, autoimmune encephalitis, vascular dementia, acute massive cerebral infarction and so on; (4) Combined with severe systemic disease, such as heart disease, hypertension, nephrosis and so on; (5) Experience fractures within six months. Have osteopathy or arthropathy which can influence gait; (6) Use implanted electronic devicessuch as cardiac pacemaker and deep brain stimulator; (7) Have a history of brain surgery; (8) Use implanted metallic materials, such as skull restore materials and vascular stent; (9) Combined with intracranial hypertension and headache; (10) Hemorrhagic tendency; (11) Combined with acute infectious diseases, fever, electrolyte disturbance and unstable vital signs; (12) Combined with neoplastic disease; (13) Skin injury, skin inflammation or hyperalgesia in the areas which are stimulated; (14) Is participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Unified-Parkinson Disease Rating Scale III;Berg Balance Scale;Five Times Sit to Stand;10 Minutes Walking Test;Timed Up and Go Test;Simple Test for Evaluating Hand Function;Mini-Mental State Examination;Stroop color-word test;

Countries

China

Contacts

Public ContactYulian Zhu

Huashan Hospital, Fudan University

zyljully@163.com+86 13816783039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026